Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure중증 호흡부전이 있는 COVID-19 환자의 구조 치료로서 흡입형 DNase, 바리시티닙 및 토실리주맙의 병용 투여Article Published on 2022-05-012022-09-12 Journal: Clinical immunology (Orlando, Fla.) [Category] Coronavirus, COVID19(2023년), SARS, 바이오마커, 임상, 진단, 치료법, [키워드] Administered administration analysed Baricitinib clinical observations Combined COVID-19 COVID-19 patient dissolve DNase duration of hospitalization fibroblasts Follow-up group hyperinflammation IL-1-receptor Immunomodulatory agent immunothrombosis in-hospital mortality Inhaled inhibited inhibitor intubation rate lung median monotherapy Neutrophil extracellular traps paO2/fiO2 pathway plasma randomized trial reduce mortality severe respiratory failure significantly Standard-of-care Support survival tissue Tissue Factor Tocilizumab Treatment [DOI] 10.1016/j.clim.2022.109016 PMC 바로가기 [Article Type] Article
Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients – A Czech multicenter experienceSARS-CoV-2에 감염된 혈액학적 환자에서 항-SARS-CoV-2 단일클론 중화 항체의 성공적인 조기 사용 - 체코의 다기관 경험Multicenter Study Published on 2022-04-012022-09-12 Journal: Hematological oncology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] administration analyzed anti-CD20 anti-SARS-CoV-2 anti-SARS-CoV-2 monoclonal neutralizing antibodies Asymptomatic asymptomatic patient bamlanivimab baseline Casirivimab Cohort Combination Course COVID-19 COVID-19 diagnosis COVID-19 mortality COVID-19 symptom Critical death diagnose diagnosed early administration early-stage COVID-19 Efficacy evaluated Final first COVID-19 symptom Follow-up General population hematological Hematological malignancy Imdevimab impair Infection leukemia leukemias lymphoma lymphomas median Mild moderate monoclonal monoclonal antibody monotherapy Mortality multicenter multicentre Neutralizing neutralizing antibody neutralizing monoclonal antibody nine occurred Patient patients plasma positive remained Result SARS-CoV-2 significantly significantly lower Spike protein survival rate therapy treated were recorded [DOI] 10.1002/hon.2974 PMC 바로가기 [Article Type] Multicenter Study
A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer Research Published on 2022-03-152022-10-05 Journal: Prostate cancer and prostatic diseases [Category] 바이오마커, 임상, [키워드] 95% CI Activation Administered anticipated Avelumab Central nervous system Complete conducted COVID-19 COVID-19 pandemic criteria CXCR2 defined disease Efficacy Endpoint enrolled Enrollment histology immune Immune cell Immunotherapy liver median median age men Metastasis monotherapy Msh2 Mutation neuroendocrine open label Patient patients PD-L1 Peripheral blood phase 2 trial Phenotyping poor prognosis positive potential mechanism primary endpoint progression progressive disease Prostate cancer Radiographic Result Safety secondary single center subset survival T-cell Response tested therapy Toxicity Treatment while [DOI] 10.1038/s41391-022-00524-7 [Article Type] Research
COVID-19 acute respiratory distress syndrome: A simulation study of the effects of combination therapy with tocilizumab and siltuximabCOVID-19 급성 호흡곤란 증후군: 토실리주맙과 실툭시맙 병용 요법의 효과에 대한 시뮬레이션 연구Article Published on 2022-03-012022-09-12 Journal: British Journal of Clinical Pharmacology [Category] SARS, 진단, [키워드] acute respiratory distress acute respiratory distress syndrome ARDS binding binding constant blockade Bronchoalveolar lavage fluid combination therapy complex component Concentration COVID-19 COVID-19 patient develop Effect generate greater IL-6 IL-6 antagonist IL-6 level IL-6 receptor IL-6R interleukin-6 Intervention literature lung Model modelling monotherapy normal predict predicted reduced reduction reflect risk SARS-COV-2 infection sequestering sIL-6R siltuximab Simulation subject subjects syndrome targets TCZ Tocilizumab treat Treatment were used [DOI] 10.1111/bcp.15009 PMC 바로가기 [Article Type] Article
Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia만성 림프구성 백혈병 환자에서 BNT162b mRNA COVID-19 백신의 안전성 및 효능Article Published on 2022-03-012022-09-11 Journal: Haematologica [Category] MERS, SARS, 진단, 치료기술, [키워드] a BTK inhibitor adverse event age Analysis anti-CD20 antibodies antibody Antibody Response BCl2 BNT162b BNT162b2 BNT162b2 mRNA BNT162b2 mRNA COVID-19 vaccine BTK inhibitor CD20 chronic lymphocytic leukemia CLL CLL patients Cohort Combination Concordance COVID-19 vaccine develop disease Efficacy eligible hemoglobin humoral IgA IgG IgM immune response individuals introduced investigated leukemia Lymphocytic leukemia monotherapy mRNA Neutralizing antibodies neutralizing antibody nine parameter Patient patients patients treated positive predict response response to vaccination Safe Safety second dose serological response Spike protein the vaccine treated treated patients Treatment treatment with anti-CD20 Vaccine [DOI] 10.3324/haematol.2021.279196 PMC 바로가기 [Article Type] Article
Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study코로나바이러스 COVID19에 따른 간질성 폐렴 환자에서 바리시티닙과 토실리주맙 단독 요법 또는 병용 요법의 사용 경험: 실제 연구Article Published on 2022-03-012022-09-12 Journal: Reumatología clinica [Category] MERS, SARS, 진단, [키워드] Admission age average Baricitinib Combined COVID-19 COVID19 died discharge English experience group ICU interstitial pneumonia males media medical record monotherapy Neumonía intersticial PaO paO2/fiO2 Patient patients patients died Quince required secondary to Side effect Side effects Spanish Symptoms TCZ Tocilizumab treated Treatment UCI. [DOI] 10.1016/j.reumae.2020.10.006 PMC 바로가기 [Article Type] Article
Comparative outcomes of combined corticosteroid and remdesivir therapy with corticosteroid monotherapy in ventilated COVID-19 patientsResearch Article Published on 2022-02-232022-10-28 Journal: PLoS ONE [Category] COVID-19, COVID19(2023년), MERS, SARS, [키워드] 48 hour all-cause mortality all-cause mortality rate analyzed Clinical improvement Cohort cohorts combination therapy Comparative conducted Corticosteroid COVID COVID-19 COVID-19 patient COVID-19 patients Cox proportional hazard Critically ill Efficacy groups hazard Hospitalized IMPROVE in-hospital mortality incidence Infection infections Kaplan-Meier Length log-rank test LOS monotherapy MRSA network Observational cohort study on mechanical ventilation outcome oxygen support Patient Primary outcome propensity score matching Pseudomona PSM Ratio RDV reduce reducing Remdesivir requiring supplemental oxygen secondary significant decrease Staphylococcus aureus stratified survival therapy Ventilated ventilatory support with COVID-19 [DOI] 10.1371/journal.pone.0264301 PMC 바로가기 [Article Type] Research Article
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer Research Published on 2022-02-112022-10-05 Journal: British Journal of Cancer [Category] 바이오마커, [키워드] 95%CI bevacizumab Biomarker Cancer clinical Combination effective expression monotherapy ovarian cancer participant Patient predict Predictive primary endpoint randomised receive regimen Result RP2 Secondary endpoints significantly stratified subgroup analysis Trial Trial registration TUBB3 [DOI] 10.1038/s41416-022-01717-6 [Article Type] Research
Emergent Virus Reactivation in SARS-CoV-2-Negative Community Acquired Pneumonia Patients During the COVID-19 PandemicMicrobiology Published on 2022-02-072022-10-31 Journal: Frontiers in Microbiology [Category] COVID-19, [키워드] absence Acquired albumin antibiotic CD4 cellular immune function Chest CT China Clinical characteristics clinical manifestation Clinical outcome CMV Community community acquired pneumonia condition COVID-19 COVID-19 pandemic Critically ill patient dry cough EBV feature Fever ground-glass opacity hemoglobin Herpesviridae HSV-1 immunosuppressed patients initial Lymphocyte count manifestation medical record monotherapy pandemic Patient patients Pneumonia positive positive patient positive rate presenting symptom Prognosis Reactivation regimen T lymphocyte therapeutic option Treatment two group university hospital upper lobe virus viruses [DOI] 10.3389/fmicb.2022.758073 PMC 바로가기 [Article Type] Microbiology
Treatment of chronic or relapsing COVID-19 in immunodeficiency면역 결핍에서 만성 또는 재발 COVID-19의 치료Article Published on 2022-02-012022-09-11 Journal: The Journal of Allergy and Clinical Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료법, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 agammaglobulinemia anti-CD20 anti-CD20 therapy anti-SARS-CoV-2 antibody B-cell characterized clearance clinical feature Clinical features Cohort cohort of patient Combination conducted convalescent plasma coronavirus disease Coronavirus disease 2019 Coronavirus-2 Course COVID-19 COVID-19 disease deficiency demographics diagnosis and demographics disease Evolution General population immunodeficiency immunodeficient patient immunodeficient patients in viral Infection infection control leads mAb median median age monoclonal monotherapy morbidity morbidity and mortality Patient promise receiving reduced relapsing Remdesivir respiratory risk SARS-CoV-2 Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus sustained symptomatic disease therapeutic therapeutic monoclonal. therapy Treatment treatment failure Treatment response Viral viral clearance Viral variants X-linked agammaglobulinemia [DOI] 10.1016/j.jaci.2021.10.031 PMC 바로가기 [Article Type] Article